FDA warns about Bystolic’s potential for drug injuries
September 11, 2008
The FDA is warning Forest Laboratories about its promotion of the hypertension drug Bystolic. The FDA says the promotions for Bystolic have failed to include risks for certain drug injuries.
The promotions for the new drug claim that the drug is better than rival drugs, but there is not sufficient evidence to prove that.
The promotions for Bystolic also leave out the potential risk for drug injuries to patients with heart conditions. These drug injuries could include cardiac arrest and chest pain.
Texas patients with heart conditions who take Bystolic could suffer Texas drug injuries such as cardiac arrest and chest pain.